The National Medical Products Administration of China (NMPA) has approved RC48 for patients with HER2-overexpressing metastatic gastric cancer/gastroesophageal junction (G/GEJ) adenocarcinoma after >2L of treatment, and HER2 IHC2+/3+ metastatic urothelial carcinoma post-platinum-based therapy. Here, ERBB2 is linked to adenocarcinoma.